International Business Machines Corporation (NYSE: IBM) is a technology stock, not an exchange-traded fund. Because the average of all current analyst targets sits only a few percentage points above the share price, the $280 central target here is not the headline consensus. Instead, it is the average of the verified analyst price targets that are above the latest closing price, rounded to a reader-friendly level. For context, the overall mean across the roughly two dozen analysts tracked is about $259, and the full target range is unusually wide—from about $174 to $300—which underscores how divided Wall Street is on the name.
Current targets above the stock price cluster mainly between roughly $250 and $300. Bank of America's Wamsi Mohan, for example, has reiterated a Buy with a $280 objective, citing software strength and cash generation, while Evercore has used a $275 price target alongside a higher sum-of-the-parts value. In contrast, more cautious voices such as UBS's David Vogt hold a Neutral (Hold) rating near $243, arguing that much of the downside has already been priced in but that the risk-reward is only now balanced. Earlier in the year, several firms carried notably higher targets—including Oppenheimer at $360—but many of those figures predate IBM's sharp 2026 pullback and are not reflected in the current average. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
IBM closed at $245.00 in its most recent session, giving the company a market value of roughly $232 billion and a trailing P/E (price-to-earnings) ratio near 21. From that level, a move to $280 implies upside of about 14%, which qualifies as a substantial move. The stock sits roughly 26% below its 52-week high of $332.46 but well above its 52-week low of $199.19, reflecting a year in which strong software results were partly offset by concerns about consulting and infrastructure growth.
Fundamentally, the company's latest quarter showed revenue growth of about 5% year over year, with software—led by Red Hat and the Data business—growing faster than the corporate average. However, much of the upside in the quarter came from deals that slipped from the prior period, making the organic improvement look more modest on closer inspection. A move toward $280 would likely require sustained software growth, a steadier consulting recovery, and continued expansion of free cash flow, which analysts model in the roughly $15 billion range for the coming year.
Several factors underpin the more bullish analyst price targets. IBM's software franchise is the strongest driver: Red Hat has grown at a double-digit pace in constant currency, and the Data segment has posted even faster growth, supporting a richer margin mix. The company also generates substantial free cash flow (FCF), which funds its dividend—currently yielding close to 2.8%—and its acquisition strategy, including the planned Confluent deal aimed at strengthening data-related offerings. Quantum computing remains a genuine source of optionality, with IBM's Quantum Day event flagged as a potential catalyst. Analysts such as Bank of America's Mohan emphasize that higher-margin software and cash generation give IBM a "defensive story with improving growth," a view that could support multiple expansion if execution holds.
The bear and neutral cases are equally concrete. Consulting demand remains soft as enterprises reassess spending amid AI disruption, and the infrastructure segment—dominated by the Z mainframe cycle—faces questions about how AI-driven code translation could eventually pressure legacy COBOL workloads. UBS's Vogt has noted "wrinkles" including low-single-digit organic software growth, mixed gross margins, and softer consulting signings, arguing the stock now trades at a fair valuation rather than a compelling discount. Valuation itself is a hurdle: after a period of multiple expansion, further gains would need to be earned through durable earnings growth rather than re-rating. Wide analyst dispersion—targets from roughly $174 to $300—signals genuine uncertainty about which path materializes.
Technically, IBM has been consolidating well below its 52-week high. The $240 area has acted as a near-term support zone, while the round $250 level and the low-$260 range mark resistance where the stock has struggled in recent weeks. The 52-week high near $332 represents the major overhead level from which the stock has already retreated sharply, and the 52-week low near $199 defines the lower bound of the current trading range. A sustained move toward $280 would require first clearing the $260 zone, a level that has repeatedly capped rallies. From what I see, reviewing the pattern history with Tickeron’s AI Pattern Search Engine helped clarify these resistance levels.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms vary in their methodology and some roll their valuation frameworks forward. The next earnings report is expected in late January, and it will be pivotal for testing software momentum, consulting stabilization, and free cash flow guidance. Investors should also monitor analyst target revisions following that report, the status and closing of the Confluent acquisition, the Quantum Day event, and any signals on infrastructure demand. Macroeconomic conditions and interest-rate expectations also matter for a name whose valuation and dividend appeal make it sensitive to shifts in the broader market outlook. I’m watching this closely as the earnings date approaches.
In my own work, I often rely on Tickeron's AI Daily Buy/Sell Signals to stay on top of shifting market dynamics. These tools apply artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals grounded in technical behavior and real-time conditions. For anyone following IBM's potential move toward $280, they offer a practical way to frame daily price action within a wider technical context without replacing deeper fundamental review.
The question of whether IBM can reach $280 ultimately hinges on execution rather than the headline number. The $280 central target represents the average of analyst targets above the current price—roughly a 14% move from $245—and reflects genuine optimism about software growth, cash generation, and quantum optionality. Yet the wide $174-to-$300 target range and the cluster of Hold ratings show that analysts are far from aligned. Sustained software momentum, a consulting recovery, and steady free cash flow would support the path higher, while soft consulting demand, mainframe competition, and valuation resistance could keep the stock range-bound. Investors should treat the target as one scenario among several and monitor earnings and analyst revisions closely, rather than as a guaranteed outcome.
One tool I keep returning to for this kind of analysis is Tickeron's AI Daily Buy/Sell Signals. It helps surface timely signals across a broad universe of names and gives me a quick sense of how technical momentum is evolving alongside the fundamental story. I find it especially useful when tracking names like IBM where price targets and sentiment can shift quickly.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
IBM moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 22 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 71%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for IBM crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +3.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBM advanced for three days, in 248 of 375 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 166 of 271 cases where IBM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
The 10-day RSI Indicator for IBM moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 27 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBM as a result. In 49 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for IBM turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
IBM broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 29 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. IBM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.700) is normal, around the industry mean (2.898). P/E Ratio (21.379) is within average values for comparable stocks, (18.492). Projected Growth (PEG Ratio) (2.087) is also within normal values, averaging (2.284). Dividend Yield (0.028) settles around the average of (0.224) among similar stocks. P/S Ratio (3.271) is also within normal values, averaging (139.965).
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of various computer products through the use of advanced information technology
Industry InformationTechnologyServices